ELOX

Eloxx Pharmaceuticals, Inc.

7 filings tracked

healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 5

Eliminated all outstanding debt through equity exchanges with Domicilium and Hercules.

debt restructure

70%

bearishMay 5

Net loss widened to $3.8M with zero product revenue and a continuing going concern warning.

earnings miss

80%

neutralMay 5

Raised $7M via pre-funded warrants, providing short-term liquidity but increasing dilution risk.

capital raise

50%

bullishMay 5

Reduced future royalty obligations to CFF to less than 1%.

margin expansion

40%

bullishMay 5

Eliminated all outstanding debt through equity exchanges with Domicilium and Hercules.

debt restructure

70%

bearishMay 5

Net loss widened to $3.8M with zero product revenue and a continuing going concern warning.

earnings miss

80%

neutralMay 5

Raised $7M via pre-funded warrants, providing short-term liquidity but increasing dilution risk.

capital raise

50%

bullishMay 5

Reduced future royalty obligations to CFF to less than 1%.

margin expansion

40%

bullishMay 5

Eliminated all outstanding debt through equity exchanges with Domicilium and Hercules.

debt restructure

70%

bearishMay 5

Net loss widened to $3.8M with zero product revenue and a continuing going concern warning.

earnings miss

80%

neutralMay 5

Raised $7M via pre-funded warrants, providing short-term liquidity but increasing dilution risk.

capital raise

50%

bullishMay 5

Reduced future royalty obligations to CFF to less than 1%.

margin expansion

40%

bullishMay 5

Eliminated all outstanding debt through equity exchanges with Domicilium and Hercules.

debt restructure

70%

bearishMay 5

Net loss widened to $3.8M with zero product revenue and a continuing going concern warning.

earnings miss

80%

neutralMay 5

Raised $7M via pre-funded warrants, providing short-term liquidity but increasing dilution risk.

capital raise

50%

bullishMay 5

Reduced future royalty obligations to CFF to less than 1%.

margin expansion

40%

bullishMay 5

Eliminated all outstanding debt through equity exchanges with Domicilium and Hercules.

debt restructure

70%

bearishMay 5

Net loss widened to $3.8M with zero product revenue and a continuing going concern warning.

earnings miss

80%

neutralMay 5

Raised $7M via pre-funded warrants, providing short-term liquidity but increasing dilution risk.

capital raise

50%

bullishMay 5

Reduced future royalty obligations to CFF to less than 1%.

margin expansion

40%

bullishMay 5

Eliminated all outstanding debt through equity exchanges with Domicilium and Hercules.

debt restructure

70%

bearishMay 5

Net loss widened to $3.8M with zero product revenue and a continuing going concern warning.

earnings miss

80%

neutralMay 5

Raised $7M via pre-funded warrants, providing short-term liquidity but increasing dilution risk.

capital raise

50%

bullishMay 5

Reduced future royalty obligations to CFF to less than 1%.

margin expansion

40%

bullishMay 5

Eliminated all outstanding debt through equity exchanges with Domicilium and Hercules.

debt restructure

70%

bearishMay 5

Net loss widened to $3.8M with zero product revenue and a continuing going concern warning.

earnings miss

80%

neutralMay 5

Raised $7M via pre-funded warrants, providing short-term liquidity but increasing dilution risk.

capital raise

50%

bullishMay 5

Reduced future royalty obligations to CFF to less than 1%.

margin expansion

40%

Filing History

10-QMay 5, 2026

The latest 10-Q paints a picture of a high-stakes binary bet on the exaluren platform. On one hand, the company has successfully cleared its balance sheet of traditional debt and secured the regulatory green light to advance its lead candidate into a pivotal trial. The shift toward non-invasive biomarkers for the Phase 2b trial suggests an optimized path to data that could significantly re-rate the stock if successful. However, the financial reality is stark. The company is operating on a razor-thin cash cushion and is heavily reliant on the issuance of pre-funded warrants to maintain solvency. Investors must weigh the genuine clinical promise of ribosome modulation against the very real risk of insolvency or extreme dilution before the mid-2027 catalyst arrives. The synthesis of this filing suggests that while the clinical path is clearing, the financial bridge to get there remains fragile.